EastGate Biotech Announces That PharmaCenter Ltd. Will Commence Marketing the Company's Nutraceutical Products

SALT LAKE CITY, UT and TORONTO, ON--(Marketwired - May 26, 2015) - EastGate Biotech Corp. (OTCBB: ETBI), an emerging pharmaceutical company aimed at utilizing drug delivery innovations in the development of improved novel formulations and alternative dosage forms of existing biologically active molecules, has announced that PharmaCenter (www.PharmaCenter.sk or www.PharmaCenter.hu) will commence marketing E-drops, one of the company's nutraceutical products in Slovakia and Czech Republic.

PharmaCenter Ltd. successfully registered E-drops with the local health authority in Slovakia and placed an initial sample order for E-drops which is the company's natural and herbal alternative that assists to rid the body of UTI infections painlessly and effectively without side effects of synthetic drugs. The initial sample order will be used for test marketing and launch in Slovakia initially before entering into the other respective markets. 

PharmaCenter Ltd. (www.PharmaCenter.sk or www.PharmaCenter.hu) is based in Hungary and has subsidiaries in Slovakia and Czech Republic. Its main focus is in the business of selling innovative oncology, urology, onco-urology, OB-GYN and orphan drugs. They offer a full range of marketing and sales services including market access support. Some of their clients include some large and mid-size pharmaceutical companies.

Information on EastGate's natural product line can be found at www.nano-essentials.com. Previously, the Company announced a distributor for its nutraceutical product line including E-drops in the United States under its own private label and in Canada with Preferred Nutrition (www.pno.ca)
.
"We are pleased to have PharmaCenter open up the market for our nutraceutical products in other countries," says Anna Gluskin, EastGate's CEO. "It is important to extend our reach to as many markets as possible to not only increase sales which enrich the bottom line, but also to gain exposure for our sub-micron delivery platform technology," continues Ms. Gluskin.

Cautionary statement on forward-looking information

All statements, other than statements of historical fact, contained or incorporated by reference in this news release constitute "forward-looking information" or "forward-looking statements" within the meaning of certain securities laws, including the provisions for "safe harbour" under the United States Private Securities Litigation Reform Act of 1995 and are based on expectations, estimates and projections as of the date of this news release.

The words "anticipates", "plans", "expects", "indicate", "intend", "scheduled", "estimates", "forecasts", "focus", "guidance", "initiative", "model", "methodology", "outlook", "potential", "projected", "pursue", "strategy", "study", "targets", or "believes", or variations of or similar such words and phrases or statements that certain actions, events or results "may", "could", "would", or "should", "might", or "way forward", "will be taken", "will occur" or "will be achieved" and similar expressions identify forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that are inherently subject to significant business, economic and competitive risks, uncertainties and contingencies. The risks, estimates, models and assumptions contained or incorporated by reference in this release, include those identified from time to time in the reports filed by EastGate with the SEC, which should be considered together with any forward-looking statement. EastGate undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT:
Rose Perri
1-647-692-0652
Email: Email Contact
Website:www.EastGateBiotech.com